CGON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CG Oncology Inc (CGON) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has promising developments in its pipeline and analyst ratings are positive, the lack of recent trading signals, insider selling, and mixed technical indicators suggest waiting for a clearer entry point.
The MACD histogram is positive at 0.145, indicating a bullish trend, but it is contracting. RSI is neutral at 53.405, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level of 55.366. Support levels are at 51.738 and 49.496, while resistance levels are at 58.995 and 61.237.
Analysts have raised price targets recently, citing positive expectations for the PIVOT-006 topline data and a large addressable market for Creto.
Significant YoY revenue growth in the latest financial quarter (up 3774.42%).
Insiders are selling heavily, with a 1311.54% increase in selling activity over the last month.
Gross margin dropped significantly by -94.66% YoY.
The stock has a 20% chance of declining in the short term based on similar candlestick patterns.
In Q3 2025, revenue surged by 3774.42% YoY to $1,666,000, and net income improved by 114.69% YoY to -$43,808,000. EPS also improved by 90% YoY to -0.57. However, gross margin dropped significantly to 5.34%, down -94.66% YoY, indicating cost pressures.
Analysts are bullish, with Truist and Wedbush maintaining Buy and Outperform ratings. Price targets have been raised to $75 and $70, respectively, citing strong potential for Creto in a large market with limited competition.
